177 related articles for article (PubMed ID: 36323067)
41. Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis.
Zuo Y; Ye L; Liu M; Li S; Liu W; Chen F; Lu X; Gordon P; Wang G; Shu X
Rheumatology (Oxford); 2020 Oct; 59(10):2829-2837. PubMed ID: 32065646
[TBL] [Abstract][Full Text] [Related]
42. Aberrantly Expressed Galectin-9 Is Involved in the Immunopathogenesis of Anti-MDA5-Positive Dermatomyositis-Associated Interstitial Lung Disease.
Liang L; Zhang YM; Shen YW; Song AP; Li WL; Ye LF; Lu X; Wang GC; Peng QL
Front Cell Dev Biol; 2021; 9():628128. PubMed ID: 33842457
[TBL] [Abstract][Full Text] [Related]
43. Clinical features of patients with anti-melanoma differentiation-associated gene-5 antibody-positive dermatomyositis complicated by spontaneous pneumomediastinum.
Yamaguchi K; Yamaguchi A; Itai M; Kashiwagi C; Takehara K; Aoki S; Sawada Y; Taguchi K; Umetsu K; Oshima K; Uchida M; Takemura M; Hara K; Motegi SI; Muro Y; Nakasatomi M; Sakairi T; Hiromura K; Kurabayashi M; Maeno T
Clin Rheumatol; 2019 Dec; 38(12):3443-3450. PubMed ID: 31420814
[TBL] [Abstract][Full Text] [Related]
44. Acute lung injury after plasma exchange in a patient with anti-MDA5 antibody-positive, rapidly progressive, interstitial lung disease：A case report.
Kagawa H; Tsujino K; Yamamoto Y; Iwai A; Hara R; Matsuki T; Fukushima K; Oshitani Y; Yoshimura K; Miki M; Miki K; Kitada S; Mori M; Kida H
Respir Med Case Rep; 2020; 29():101016. PubMed ID: 32055439
[TBL] [Abstract][Full Text] [Related]
45. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis.
Chen Z; Cao M; Plana MN; Liang J; Cai H; Kuwana M; Sun L
Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1316-24. PubMed ID: 23908005
[TBL] [Abstract][Full Text] [Related]
46. Cytokeratin 19 fragment is associated with severity and poor prognosis of interstitial lung disease in anti-MDA5 antibody-positive dermatomyositis.
Gui X; Ma M; Ding J; Shi S; Xin X; Qiu X; Zhang Y; Qiu Y; Cao M; Huang M; Cao M; Dai J; Cai H; Xiao Y
Rheumatology (Oxford); 2021 Aug; 60(8):3913-3922. PubMed ID: 33501503
[TBL] [Abstract][Full Text] [Related]
47. Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis.
Ishikawa Y; Iwata S; Hanami K; Nawata A; Zhang M; Yamagata K; Hirata S; Sakata K; Todoroki Y; Nakano K; Nakayamada S; Satoh M; Tanaka Y
Arthritis Res Ther; 2018 Oct; 20(1):240. PubMed ID: 30367666
[TBL] [Abstract][Full Text] [Related]
48. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease.
Sato S; Kuwana M; Fujita T; Suzuki Y
Mod Rheumatol; 2013 May; 23(3):496-502. PubMed ID: 22644102
[TBL] [Abstract][Full Text] [Related]
49. A Retrospective Analysis of Outcome in Melanoma Differentiation-Associated Gene 5-Related Interstitial Lung Disease Treated with Tofacitinib or Tacrolimus.
Fan L; Lyu W; Liu H; Jiang H; Chen L; Liu Y; Zhuang Y; Huang M; Cao M; Cai H; Xiao Y; Dai J
J Rheumatol; 2022 Dec; 49(12):1356-1364. PubMed ID: 35970525
[TBL] [Abstract][Full Text] [Related]
50. Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis.
Sakamoto N; Ishimoto H; Nakashima S; Yura H; Miyamura T; Okuno D; Hara A; Kitazaki T; Kakugawa T; Ishimatsu Y; Satoh M; Mukae H
Intern Med; 2019 Mar; 58(6):837-841. PubMed ID: 30449789
[TBL] [Abstract][Full Text] [Related]
51. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis.
Gono T; Sato S; Kawaguchi Y; Kuwana M; Hanaoka M; Katsumata Y; Takagi K; Baba S; Okamoto Y; Ota Y; Yamanaka H
Rheumatology (Oxford); 2012 Sep; 51(9):1563-70. PubMed ID: 22589330
[TBL] [Abstract][Full Text] [Related]
52. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis.
Ida T; Furuta S; Takayama A; Tamura J; Hayashi Y; Abe K; Kurihara S; Ishikawa J; Iwamoto T; Ikeda K; Suzuki K; Nakajima H
RMD Open; 2023 Jan; 9(1):. PubMed ID: 36593080
[TBL] [Abstract][Full Text] [Related]
54. Seasonal Effect on Disease Onset and Presentation in Anti-MDA5 Positive Dermatomyositis.
So H; So J; Lam TT; Wong VT; Ho R; Li WL; Lau CS; Tam LS
Front Med (Lausanne); 2022; 9():837024. PubMed ID: 35187011
[TBL] [Abstract][Full Text] [Related]
55. Intensive induction therapy combining tofacitinib, rituximab and plasma exchange in severe anti-melanoma differentiation-associatedprotein-5 antibody-positive dermatomyositis.
Shirai T; Machiyama T; Sato H; Ishii T; Fujii H
Clin Exp Rheumatol; 2023 Mar; 41(2):291-300. PubMed ID: 36700661
[TBL] [Abstract][Full Text] [Related]
56. Anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease treated with therapeutic plasma exchange: A case series.
Saito T; Mizobuchi M; Miwa Y; Sugiyama M; Mima Y; Iida A; Kanazawa N; Morikawa T; Hayashi J; Fukuda K; Shikida Y; Suzuki T; Honda H
J Clin Apher; 2021 Feb; 36(1):196-205. PubMed ID: 32823371
[TBL] [Abstract][Full Text] [Related]
57. Serum interleukin-34 levels in dermatomyositis: a potential biomarker for anti-MDA5-antibody-associated interstitial lung disease.
Kuzumi A; Fukasawa T; Yamashita T; Matsuda KM; Kotani H; Yoshizaki-Ogawa A; Sato S; Yoshizaki A
Rheumatology (Oxford); 2024 Jun; ():. PubMed ID: 38830088
[TBL] [Abstract][Full Text] [Related]
58. Neutrophil extracellular traps may contribute to interstitial lung disease associated with anti-MDA5 autoantibody positive dermatomyositis.
Peng Y; Zhang S; Zhao Y; Liu Y; Yan B
Clin Rheumatol; 2018 Jan; 37(1):107-115. PubMed ID: 28842784
[TBL] [Abstract][Full Text] [Related]
59. Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: A systematic review.
McPherson M; Economidou S; Liampas A; Zis P; Parperis K
Semin Arthritis Rheum; 2022 Apr; 53():151959. PubMed ID: 35134633
[TBL] [Abstract][Full Text] [Related]
60. α2,3-Sialylation with Fucosylation Associated with More Severe Anti-MDA5 Positive Dermatomyositis Induced by Rapidly Progressive Interstitial Lung Disease.
Zhang R; Guo L; Sha J; Chang S; Zhao J; Wang K; Wang J; Gu J; Liu J; Ren S
Phenomics; 2023 Oct; 3(5):457-468. PubMed ID: 37881316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
